HDAC9 and myeloid sarcoma: HDAC9 [−0.72%, bootstrapped 95% CI: (−0.10, −1.37), P = 0.014] and HLA-DRB1*1501 correlated with reduced 30-year GMF [−0.62%, bootstrapped 95% CI: (0.00, −1.36), P = 0.030], although HLA-DRB1*1501 was not significant after including WM lesion volume within the model (HLA-DRB1*1501; P = 0.239; WM lesion volume P = 0.039) and no association was seen between HLA-DRB1*1501 and GMF in the MS-only subgroup.